https://player.vimeo.com/video/672264702
PALYNZIQ BioMarin 1_14_22_Kellen - FINAL.mp4 on Vimeo
biomarinkellenfinalvimeo
https://www.benzinga.com/analyst-ratings/analyst-color/21/09/22872723/stifel-upgrades-this-pharma-stock-on-prospective-fda-approval-for-dwarfism-drug
Stifel Upgrades This Pharma Stock On Prospective FDA Approval For Dwarfism Drug - BioMarin...
https://clinicaltrials.biomarin.com/
BioMarin Pharmaceutical Inc.
Mar 19, 2026 - Learn about our efforts to translate the promise of genetic discovery into medicines that have a profound impact on the life of each patient.
biomarinpharmaceuticalinc
https://jobs.jobvite.com/biomarin/job/o2eRyfwp
BioMarin Pharmaceutical Inc. Careers - Country Director - China
BioMarin Pharmaceutical Inc. is looking for Country Director - China. Learn more or Jobvite a friend.
country directorbiomarinpharmaceuticalinccareers
https://www.nasdaq.com/market-activity/stocks/bmrn/dividend-history
BioMarin Pharmaceutical Inc. Common Stock (BMRN) Dividend History | Nasdaq
Stay up-to-date on BioMarin Pharmaceutical Inc. Common Stock (BMRN) Dividends, Current Yield, Historical Dividend Performance, and Payment Schedule.
common stockdividend historybiomarinpharmaceuticalinc
https://palynziq.biomarin.com/en-us/
Home - BioMarin Palynziq Patient EN-US
Apr 28, 2026 - PALYNZIQ® (pegvaliase-pqpz) Injection for the treatment of phenylketonuria (PKU). Find out how managing PKU (phenylketonuria) differently could help achieve...
biomarinpatientus
https://www.oanda.com/eu-ro/trading/shares/us/biomarin-pharmaceutical
Biomarin Pharmaceutical Inc (BMRN) Trading | Shares / Shares CFDs | OANDA
Trade Biomarin Pharmaceutical Inc (BMRN) shares CFDs with OANDA. View live charts and current market interest for this stock.
trading sharesbiomarinpharmaceuticalinccfds
https://www.sintef.no/alle-ansatte/ansatt/bendik.toldnes/
Bendik Toldnes - Fiskeri og ny biomarin industri - SINTEF Ocean AS - SINTEF
fiskeri ogbendiknybiomarinindustri
https://www.biopharmadive.com/news/fda-rejection-biomarin-gilead-roctavian-filgotinib/583776/
In major surprise, FDA rejects high-profile therapies from BioMarin, Gilead | BioPharma Dive
BioMarin's hemophilia gene therapy Roctavian and Gilead's arthritis drug filgotinib were widely expected to win approvals from the FDA, which demanded more...
https://www.fool.com/investing/general/2016/03/02/biomarin-ratchets-up-the-profitability-talk.aspx
BioMarin Pharmaceutical Inc. Ratchets Up the Profitability Talk | The Motley Fool
Mar 2, 2016 - Investors will have to wait until next year, though.
biomarinpharmaceuticalincratchetsprofitability
https://www.biomarin.com/careers/
Biotechnology and Pharmaceutical Careers | BioMarin
Jul 8, 2026 - Our employees include some of the most talented professionals in the biopharma industry. Learn more about career opportunities at BioMarin and explore openings...
biotechnologypharmaceuticalcareersbiomarin
https://hcp.biomarin.com/en-gb/cln2/expert/
CLN2 Expert - BioMarin CLN2 Expert HCP EN-GB
Apr 28, 2026 - CLN2 Expert has been developed as a scientific and educational resource for healthcare professionals, dedicated to advancing knowledge, collaboration and...
expertbiomarinhcpengb
https://www.fiercebiotech.com/medtech/deep-genomics-hits-partnering-ground-running-biomarin-deal
Deep Genomics hits the partnering ground running with BioMarin deal | Fierce Biotech
Nov 17, 2020 - Deep Genomics is wasting no time.
deep genomics
https://www.fool.ca/company/nasdaq-bmrn-biomarin-pharmaceutical/339603/
BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Price & News | The Motley Fool Canada
See the latest BioMarin Pharmaceutical (NASDAQ:BMRN) stock price, company analysis, news, and price history from our investing experts.
the motley foolstock pricebiomarinpharmaceuticalnasdaq
https://markets.businessinsider.com/news/stocks/wells-fargo-says-buy-biomarin-shares-amid-phase-2-trial-discontinuation-weakness-1035935108
Wells Fargo says buy BioMarin shares amid Phase 2 trial discontinuation weakness | Markets Insider
BioMarin (BMRN) announced Monday the discontinuation of three Voxzogo Phase 2 studies in Turner Syndrome, SHOX-difficiency, and ACAN-difficiency...
https://www.prnewswire.com/news-releases/ongoing-clinical-trials-reveal-groundbreaking-results---research-report-on-alexion-biomarin-onyx-questcor-and-immunogen-211533701.html
Ongoing Clinical Trials Reveal Groundbreaking Results - Research Report on Alexion, BioMarin, Onyx,...
/PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical...
ongoing clinical trials
https://www.veeva.com/resources/veeva-and-biomarin-form-long-term-strategic-partnership/
Veeva and BioMarin Form Long-Term Strategic Partnership | Veeva
Apr 7, 2026 - Partnership to help BioMarin increase speed and efficiency in developing and commercializing innovative therapies.
long termveevabiomarinformstrategic
https://public.com/stocks/bmrn/options-chain
Buy BioMarin Pharmaceutical (BMRN) Call and Put Options - Options Chain
call and put optionsbuybiomarinpharmaceuticalchain
https://web.cvent.com/event/3dd5319f-7175-4d9a-b57c-e958ef59e85a/summary
Archived Event - BioMarin PKU Adolescent Advisory Board - BioMarin Registration
advisory boardarchivedeventbiomarinpku
https://medical.biomarin.com/
Home | BioMarin Medical Global
Dec 16, 2025 - The BioMarin Medical website is intended for use by healthcare professionals and provides a broad range of resources, including publications, congress and...
biomarinmedicalglobal
https://www.bmrn.co.jp/
BioMarin Pharmaceutical Japan - バイオマリンは希少疾患を対象とした、画期的なバイオ医薬品を開発・提供している製薬会社です。
BioMarin Pharmaceutical Japan 株式会社（バイオマリン）は希少疾患を対象とした、画期的なバイオ医薬品を開発・提供している製薬会社です。
biomarinpharmaceuticaljapan